RE:RE:RE:RE:Roche CD47 antibody start-up gives up-lays off all employees June 14, 2024 - Gilead Sciences' abandoned anti-CD47 drug magrolimab was not just ineffective, but could potentially be harmful to patients with untreated high-risk myelodysplastic syndrome, according to new data from a phase 3 study presented at 2024’s European Hematology Association (EHA) meeting.
Magrolimab showed worse performances compared with placebo across multiple efficacy and safety metrics in their respective combinations with chemotherapy, data from the ENHANCE trial have shown.
The magrolimab-chemo regimen was tied to a 20.3% increased risk of death, though the results were not statistically significant, with a p-value of 0.13. Patients who got the investigational therapy lived a median 15.9 months, versus 18.6 months for those in the control arm.
On the trial's other primary endpoint, the complete remission rate (CRR) was numerically lower at 21.3% for patients receiving magrolimab, versus 23.6% for the placebo group.
Gilead had already slammed the brakes on the ENHANCE study after a prespecified interim analysis indicated that it likely wouldn't succeed.
https://www.fiercebiotech.com/biotech/new-eha-data-reveal-how-gileads-49b-bet-cd47-imploded